Does cancer risk affect health-related quality of life in patients with Barrett's esophagus? - PubMed (original) (raw)
Comment
Does cancer risk affect health-related quality of life in patients with Barrett's esophagus?
Lauren B Gerson et al. Gastrointest Endosc. 2007 Jan.
Abstract
Background: Health-related quality of life is decreased in patients with GERD and Barrett's esophagus (BE).
Objective: To determine whether time-tradeoff (TTO) values would differ in patients with BE when patients were asked to trade away the potential risk of esophageal adenocarcinoma rather than chronic heartburn symptoms.
Design: A prospective clinical trial.
Patients: Subjects with biopsy-proven BE.
Interventions: Custom-designed computer program to elicit health-state utility values, quality of life in reflux and dyspepsia (QOLRAD), and Medical Outcomes Survey short form-36 surveys.
Main outcome measurements: TTO utility values for the annual cancer-risk-associated current health state and for hypothetical scenarios of dysplasia and esophageal cancer.
Results: We studied 60 patients in the cancer-risk cohort (57 men, 92% veteran; mean age [standard deviation; SD], 65 years [11 years], mean GERD duration 17 years [12 years]). The heartburn cohort included 40 patients with GERD and BE with TTO values derived for GERD symptoms. The mean (SD) utility for nondysplastic BE was 0.91 (0.13) compared with 0.90 (0.12) for the heartburn cohort (P = .7). The mean utility values were significantly lower for scenarios of low-grade dysplasia (0.85 [0.12], P = .02) and high-grade dysplasia (0.77 [0.14], P < .005). The mean TTO was 0.67 (0.19) for the scenario of esophageal cancer. There was no correlation between the utility scores and the disease-specific survey scores.
Limitations: TTO values were hypothetical for states of dysplasia and cancer.
Conclusions: TTO utility values based on heartburn symptoms or annual risk of cancer in patients with nondysplastic BE are roughly equivalent. However, TTO utility values are significantly lower for health states with increasing cancer risks.
Comment on
- Barrett's esophagus and the costs of "doing something".
Dellon ES, Shaheen NJ. Dellon ES, et al. Gastrointest Endosc. 2007 Jan;65(1):31-5. doi: 10.1016/j.gie.2006.07.015. Gastrointest Endosc. 2007. PMID: 17185077 No abstract available.
Similar articles
- Hiatal hernia size, Barrett's length, and severity of acid reflux are all risk factors for esophageal adenocarcinoma.
Avidan B, Sonnenberg A, Schnell TG, Chejfec G, Metz A, Sontag SJ. Avidan B, et al. Am J Gastroenterol. 2002 Aug;97(8):1930-6. doi: 10.1111/j.1572-0241.2002.05902.x. Am J Gastroenterol. 2002. PMID: 12190156 - Patient-derived health state utilities for gastroesophageal reflux disease.
Gerson LB, Ullah N, Hastie T, Triadafilopoulos G, Goldstein M. Gerson LB, et al. Am J Gastroenterol. 2005 Mar;100(3):524-33. doi: 10.1111/j.1572-0241.2005.40588.x. Am J Gastroenterol. 2005. PMID: 15743346 Clinical Trial. - Health-related quality of life and severity of symptoms in patients with Barrett's esophagus and gastroesophageal reflux disease patients without Barrett's esophagus.
Eloubeidi MA, Provenzale D. Eloubeidi MA, et al. Am J Gastroenterol. 2000 Aug;95(8):1881-7. doi: 10.1111/j.1572-0241.2000.02235.x. Am J Gastroenterol. 2000. PMID: 10950030 - Barrett's esophagus and risk of esophageal adenocarcinoma.
Cossentino MJ, Wong RK. Cossentino MJ, et al. Semin Gastrointest Dis. 2003 Jul;14(3):128-35. Semin Gastrointest Dis. 2003. PMID: 14653412 Review. - Treatment of Barrett's esophagus with high-grade dysplasia.
McAllaster JD, Buckles D, Al-Kasspooles M. McAllaster JD, et al. Expert Rev Anticancer Ther. 2009 Mar;9(3):303-16. doi: 10.1586/14737140.9.3.303. Expert Rev Anticancer Ther. 2009. PMID: 19275509 Review.
Cited by
- Treatment of Barrett's esophagus with high-grade dysplasia or cancer: predictors of surgical versus endoscopic therapy.
Yachimski P, Nishioka NS, Richards E, Hur C. Yachimski P, et al. Clin Gastroenterol Hepatol. 2008 Nov;6(11):1206-11. doi: 10.1016/j.cgh.2008.04.031. Epub 2008 Jul 10. Clin Gastroenterol Hepatol. 2008. PMID: 18619919 Free PMC article. - Health-related quality of life in patients with Barrett's esophagus: a systematic review.
Crockett SD, Lippmann QK, Dellon ES, Shaheen NJ. Crockett SD, et al. Clin Gastroenterol Hepatol. 2009 Jun;7(6):613-23. doi: 10.1016/j.cgh.2009.02.024. Epub 2009 Mar 10. Clin Gastroenterol Hepatol. 2009. PMID: 19281858 Free PMC article. Review. - Quality of life, clinical outcomes and cost utilization of endoscopic therapy in patients with Barrett's esophagus and early esophageal cancer-an 8-year Canadian experience.
David J, Woo M, Congly S, Andrews CN, Jeyalingam T, Belletrutti PJ, Gupta M. David J, et al. J Can Assoc Gastroenterol. 2024 Jun 26;7(5):368-375. doi: 10.1093/jcag/gwae018. eCollection 2024 Oct. J Can Assoc Gastroenterol. 2024. PMID: 39416720 Free PMC article. - American Gastroenterological Association technical review on the management of Barrett's esophagus.
Spechler SJ, Sharma P, Souza RF, Inadomi JM, Shaheen NJ; American Gastroenterological Association. Spechler SJ, et al. Gastroenterology. 2011 Mar;140(3):e18-52; quiz e13. doi: 10.1053/j.gastro.2011.01.031. Gastroenterology. 2011. PMID: 21376939 Free PMC article. Review. No abstract available. - Health-Related Quality of Life Associated with Barrett's Esophagus and Cancer.
Bulamu NB, Chen G, Ratcliffe J, Schloite A, Bright T, Watson DI. Bulamu NB, et al. World J Surg. 2019 Jun;43(6):1554-1562. doi: 10.1007/s00268-019-04936-w. World J Surg. 2019. PMID: 30719557
Publication types
MeSH terms
LinkOut - more resources
Full Text Sources